Kronos Bio, Inc. (KRON)
|Net Income (ttm)||-25.05M|
|Trading Day||January 25|
|Day's Range||31.44 - 33.39|
|52-Week Range||26.68 - 38.23|
Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
MYC amplification found in approximately 30% of solid tumors
SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today ann...
Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N PM1-mutated acute myeloid leukemia
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today anno...
After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular wa...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a clinical-stage biopharmaceutical company dedicated to the discovery and development...
U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week
Shares of Kronos Bio Inc. soared in their public debut, as they opened 50% above the initial public offering price. The stock's first trade was at $28.50 at 11:58 a.m.
This week has down with 6 IPOS scheduled for Thursday and Friday. FuboTV: Sport first live tv streaming company Fubo TV (OTC: FUBO) is uplisting to the Nasdaq.
Kronos Bio Inc. priced its upsized initial public offering at $19 a share, above its $16 to $18 price range. The California-based biotech sold 13.2 million shares to raise about $250.8 million.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cance...
Kronos Bio Inc. KRON, disclosed Thursday that its initial public offering was upsized by about 28%, as the California-based biopharmaceutical now looks to raise up to $236.8 million
Kronos Bio, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified ... [Read more...]
Research and Development in Biotechnology
|IPO Date |
Oct 9, 2020
Dr. Norbert W. Bischofberger
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for Kronos Bio stock is "Buy." The 12-month stock price forecast is 43.67, which is an increase of 37.76% from the latest price.